Drug · CHEMBL27
PROPRANOLOL
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. PROPRANOLOL. Drugs and targets, record CHEMBL27. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL27
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- .beta.-propranolol, AY-64043-, Betalong, Dl-propranolol, Euprovasin, Inderide-40/25, Inderide-80/25, Proprasylyt, Reducor
- ChEMBL
- Open Targets' highest stage
- Approval, for 3 of its 133 diseases, from ATC, EMA Human Drugs and TTD
- Open Targets
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ADRB1 | Beta-1 adrenergic receptor | Beta-1 adrenergic receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/153 |
| ADRB2 | Beta-2 adrenergic receptor | Beta-2 adrenergic receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/154 |
Source ChEMBL
Diseases133
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 133Source Open Targets
See all 133 diseasesTrials315
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 85 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00673309 | Assessment of Mechanisms of Improved Wound Healing | Phase 2/3 | 644 | 2019-12-16 | propranolol | Its name | ClinicalTrials.gov |
| NCT01056341 | Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy | Phase 2/3 | 512 | 2014-06-24 | propranolol | Its name | ClinicalTrials.gov |
| NCT02342275 | Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma | Phase 3 | 377 | 2022-06-16 | propranolol | Its name | ClinicalTrials.gov |
| NCT02620579 | Biopsychosocial Influence on Shoulder Pain | Phase 2 | 264 | 2023-01-13 | propranolol | Its name | ClinicalTrials.gov |
| NCT01060111 | An Efficacy and Tolerability Study of Topiramate in Participants With Migraine | Phase 4 | 250 | 2013-08-06 | propranolol | Its name | ClinicalTrials.gov |
| NCT03348683 | Propranolol Versus Placebo for Induction of Labor in Nulliparous Patients | Phase 2 | 240 | 2019-12-26 | propranolol | Its name | ClinicalTrials.gov |
| NCT00910689 | Drug and Non-Drug Treatment Of Severe Migraine | Phase 4 | 232 | 2009-06-01 | propranolol | Its name | ClinicalTrials.gov |
| NCT02437383 | Study of Orofacial Pain and PropRANOlol | Phase 2 | 200 | 2019-05-21 | propranolol | Its name | ClinicalTrials.gov |
| NCT00772031 | NINDS CRC Chronic Migraine Treatment Trial | Phase 3 | 191 | 2012-01-19 | propranolol | Its name | ClinicalTrials.gov |
| NCT01631682 | Pilot Study of Pharmaceutical and Behavioral Interventions to Treat Anxiety Disorders | Phase 4 | 186 | 2017-02-23 | propranolol | Its name | ClinicalTrials.gov |
1 to 10 of 315
See all 315 trialsComparisons in its trials80
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Propranolol or Carvedilol vs Atenolol, Bisoprolol or Sotalol: deaths from any cause | 0 of 222,015 | 0 of 222,015 | 444,030 | NCT05794997 | Trial comparisons |
| Propranolol vs Atenolol: Successful Initial Response | 171 of 190 | 163 of 187 | 377 | NCT02342275 | Trial comparisons |
| Propranolol vs Atenolol: The Primary Outcome Measure Was Any Response at 6 Months | 178 of 190 | 173 of 187 | 377 | NCT02342275 | Trial comparisons |
| Propranolol vs Atenolol: deaths from any cause | 0 of 190 | 0 of 187 | 377 | NCT02342275 | Trial comparisons |
| Propranolol vs Atenolol: Number of Participants With Complete/Nearly Complete Response (96 Week) | 156 of 190 | 149 of 187 | 377 | NCT02342275 | Trial comparisons |
| Propranolol vs Atenolol: serious adverse events | 5 of 190 | 3 of 187 | 377 | NCT02342275 | Trial comparisons |
| Propranolol vs Atenolol: Rebound Rate | 19 of 170 | 12 of 160 | 330 | NCT02342275 | Trial comparisons |
| Propranolol vs Placebo: Number of Fetus With Heart Rate Decelerations | 15 of 121 | 13 of 119 | 240 | NCT03348683 | Trial comparisons |
| Propranolol vs Placebo: Number of Neonates With Neonatal Outcome Composite Score = 1 | 21 of 121 | 28 of 119 | 240 | NCT03348683 | Trial comparisons |
| Propranolol vs Placebo: Number of Participants With Postpartum Hemorrhage | 15 of 121 | 26 of 119 | 240 | NCT03348683 | Trial comparisons |
1 to 10 of 80
See all 80 comparisons in its trialsPapers from its trials159
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials17
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Category Fluency | 2 | 0 | ConductCognition |
| Verbal Fluency | 2 | 0 | ConductCognition |
| Cancellation Test | 1 | 0 | ConductCognition |
| Corsi Block-Tapping Test | 1 | 0 | ConductCognition |
| Effort Discounting Task | 1 | 0 | ConductCognition |
| Emotional Stroop Task | 1 | 1 | ConductCognition |
| Food Cue Reactivity Task | 1 | 1 | ConductCognition |
| Go/No-Go Task | 1 | 0 | ConductCognition |
| 1-Back Task | 1 | 1 | ConductCognition |
| 2-Back Task | 1 | 1 | ConductCognition |
1 to 10 of 17
See all 17 tests in its trialsData dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL27
GET https://conductscience.org/api/drugs/v1/CHEMBL27/diseases?page=2